Hypothesis: After liver transplantation, patients with stage III hepatocellular carcinoma (HCC) experience survivals similar to those of patients with less advanced disease and of matched control subjects.
we performed 635 adult liver transplantations, including 51 (8%) in patients with HCC. One hundred fiftyone patients without HCC who underwent transplantation were selected as controls. Patient demographic features were similar between case-control groups. The overall 5-year survival trend was worse for patients with HCC vs their matched controls (48% vs 65%; P = .07); however, this survival disadvantage was eliminated when patients with stages I through III HCC were combined and compared with their matched controls (59% vs 63%; P=.96). Survival of patients with stage III disease was comparable to that of matched controls (65% vs 59%; P=.44).
Conclusions: For patients with stages I through III disease, long-term survival is comparable to that of matched controls, and only patients with stage IV disease experience poorer survival. Consideration should be given to granting exception points to patients with stage III disease.
Arch Surg. 2005; 140:459-464 I N THE PAST 2 DECADES, HEPATOcellular carcinoma (HCC) has emerged as a growing health threat in the developed world. In the United States alone, the incidence has almost doubled. 1 As patients with chronic viral hepatitis age, the incidence of HCC is expected to grow significantly. Historically, surgical resection was the only treatment available, and 5-year survival in selected patients undergoing resection approached 60%. 2 However, more than 75% of patients present with associated cirrhosis that precludes standard resection. 3 In addition, even when patients are able to undergo successful resection, there is a high rate of tumor recurrence in the remnant liver, with long-term diseasefree survivals of only 20% to 30%. 4 Early experience with liver transplantation for HCC was disappointing, with reported 1-year survival frequently less than 50%. [5] [6] [7] More recently, liver transplantation has resurfaced as a practical alternative in patients with unresectable disease. In 1996, Mazzaferro et al 8 published their largely unprecedented results with liver transplantation in a highly selected group of patients with HCC (hereafter referred to as HCC patients). Subsequently, the United Network for Organ Sharing (UNOS) adopted the Milan criteria as guidelines for determining eligibility for transplantation in HCC patients, thereby limiting transplantation to recipients with stage I or II disease. Using these criteria, long-term outcomes have met or exceeded those recognized after resection. 7 Analysis of UNOS data on transplantation for HCC demonstrates a recent increase in the 5-year survival rate to 61.1%, which is presumptively attributed to improved patient selection. 9 Furthermore, there are now reports of success after transplantation in individuals whose tumor burden exceeds the Milan criteria.
To validate these more recent reports, we examined our institutional experience with liver transplantation for HCC during a 17-year period. The survival of HCC patients undergoing transplantation was compared with that of a matched, non-HCC cohort undergoing transplantation during the same period. Stage-specific outcome was also examined. This study confirms our hypothesis that HCC patients with stage III disease may fare as well after liver transplantation as those patients with less advanced disease if careful selection criteria are used.
METHODS
We reviewed data from all liver transplant recipients at Washington University, St Louis, Mo, from August 1, 1985 , to February 28, 2002 . Using a prospectively maintained database, we identified 51 HCC patients who had received liver transplants during the period of interest. These patients were matched with a contemporary cohort of 153 patients without HCC (a 3:1 matching scheme) who underwent liver transplantation at the same institution. When possible, patients were matched by age, sex, year of transplantation, and underlying etiology of cirrhosis. Patients younger than 18 years and those requiring urgent or emergent liver transplantation were excluded from analysis. The study was approved by the Human Studies Committee at Washington University.
Tumor staging was determined from pathological data obtained from the explanted specimens using the American Liver Tumor Study Group modified TNM staging classification ( Table 1) . 12 This staging system is currently used by UNOS in determining eligibility for exception points. In selected patients, chemoembolization and tumor ablation were performed while awaiting transplantation; however, the effect of neoadjuvant therapy was not assessed as part of the present study. The primary end points were overall survival and recurrence rate. Overall survival was defined as the time from initial transplantation to patient death. Recurrence was determined by using laboratory or imaging study results suggestive of HCC after transplantation. Patients who underwent retransplantation were censored from further analysis at that time.
We calculated means and standard deviations for continuous variables, and performed statistical analysis using 2-tailed t tests and Fisher exact tests as appropriate. We constructed survival curves using Kaplan-Meier estimates and analyzed them using the log-rank test. We used Microsoft Excel 2002 (Microsoft Corp, Redmond, Wash) and GraphPad Prism software, version 4.02 (GraphPad Software Inc, San Diego, Calif ) for analysis. PϽ.05 was considered significant.
RESULTS
During the study period, 635 adult liver transplantations were performed at our institution. Fifty-one HCC patients underwent transplantation, constituting 8% of the total. The mean age at transplantation was 51.9 years, with a predominance of men and a racial distribution representative of our referral pattern ( Table 2) . More than half (28 patients [55%]) of the HCC patients had known viral hepatitis (hepatitis B or C), with HCC developing in the remainder in the setting of alcoholic (10 patients [20%]) or other cirrhotic (13 patients [25%]) etiologies. The HCC patients were matched to 153 patients undergoing transplantation for liver disease without evidence of malignancy (non-HCC cohort). Age, sex, race, and hepatitis B or C as the cause of liver failure were not significantly different between groups (Table 2) . Median lengths of follow-up for HCC and non-HCC patients were 37 and 53 months, respectively (P=.02). This difference in follow-up can be attributed to the poor survival of HCC patients with stage IV disease, as median follow-up for patients with stages I to III disease was not significantly different from that of their matched controls (48 vs 44 months; P=.82). Stage distribution of HCC patients is shown in Table 3 .
As depicted in Figure 1 , median 5-year survival for all HCC patients undergoing transplantation was 48%, compared with 65% for the non-HCC cohort (P=.07). The 1-, 3-, and 5-year survivals based on HCC stage are shown in Table 4 and Figure 2 . Overall survival for patients with stage III disease was not statistically different from that of patients with stage I (P=.70) or stage II (P = .44) disease. Conversely, patients undergoing transplantation for stage IV disease fared significantly worse than those with less advanced disease, with a median 5-year survival of 26%. When compared with the non-HCC matched cohort (Table 5) , only patients with stage IV disease experienced significantly worse survival than their matched controls (P = .002), with patients with stage I, II, and III disease demonstrating 5-year survivals equivalent to those of patients without malignancy. Specifically, patients with stage III disease did no worse than their matched controls at the 1-, 3-, and 5-year times ( Table 6 ). Considering patients with stages I, II, and III disease as a group, survival was not significantly different from that of matched controls (Figure 3) (P= .96).
Recurrent or metastatic disease developed in 13 HCC patients (25%). Eleven of these patients (85%) had stage IV disease. No recurrence developed in any patient with stage I disease undergoing transplantation, whereas recurrent HCC developed in 1 patient each with stage II (7%) and stage III (11%) disease. The overall mean time to recurrence was 10 months.
COMMENT
Hepatocellular carcinoma is a rising health problem in the United States, with the incidence nearly doubling from the 1970s to the 1990s. 1 In addition, the explosion in the number of hepatitis C cases, which peaked in the late 1980s, will be expected to produce a similar peak in HCC approximately 20 to 30 years later. 13, 14 Although surgical resection has traditionally been considered the gold standard of treatment, long-term survival is generally disappointing, with most series reporting 5-year survivals ranging from 32% to 44% in cirrhotic patients undergoing partial hepatectomy for HCC. [15] [16] [17] [18] In addition, longer follow-up demonstrates a high rate of recurrence in the remnant liver due to intrahepatic spread and the development of second primary tumors associated with the underlying hepatic disease. Furthermore, patients with moderate to severe cirrhosis typically are not candidates for resection. Less invasive therapies such as chemoembolization and ethanol or radiofrequency ablation have produced only modest success. 19, 20 Historically, transplantation for HCC was met with significant resistance because of less-than-favorable outcomes. Long-term survival was unusual, and recurrence of disease was frequent. 21, 22 Paralleling an improvement in outcomes after liver transplantation for all causes has been an improved survival after transplantation for HCC. Both modern immunosuppressive regimens and stricter patient selection are believed to have contributed to this shift in outcomes. 23 After thereportofMazzaferroetal, 8 transplantationforHCCgained renewed interest. Subsequent studies confirmed that patients withsmallertumorswhounderwenttransplantationenjoyed favorable long-term survival. [24] [25] [26] Beginning in 2002 and coincident with the change in liver allocation procedures using the model for end-stage liver disease score, patients with early-stage HCC have been given special priority. 27 Based on the Milan criteria, patients with stages I and II disease are allottedamodelforend-stageliverdiseasepriorityscorehigher than what might be calculated on the basis of liver function alone. This has resulted in an increase in both the absolute number and the proportion of patients undergoing transplantation for HCC, and waiting time and waiting-list mortality rates have decreased significantly. 28 Nevertheless, the dropout rate for patients with HCC remains high, with 50% of patients with large or multiple tumors becoming ineligible for transplantation within 1 year. 29 In light of limited organ availability and rapid disease progression in some patients, transplantation for HCC should be offered only to patients whose survival is predicted to be similar to that of patients receiving transplants for benign disease. 30 Recently, there have been reports of extended survival after transplantation in patients with more advanced HCC. On the basis of their experience with transplantation for large HCC, Yao et al 10 proposed expanding transplantation eligibility criteria to include patients with solitary tumors having diameters of less than 6.5 cm, or patients with fewer than 4 nodules, with the largest lesion smaller than 4.5 cm and total tumor diameter not exceeding 8 cm. Under these criteria, the authors reported a 5-year survival of 75.2%. Of these patients, 12% had tumors greater than 5 cm in diameter. Others have demonstrated that recurrencefree survival is not significantly different between patients who did or did not meet UNOS criteria. 31 Using a combination of preoperative adjuvant chemotherapy and subsequent liver transplantation, Roayaie et al 11 achieved durable long-term survival in patients with tumors greater than 5 cm. Similarly, Gondolesi et al 32 reported their experience with living donor liver transplantation for early-and late-stage HCC. These patients, 53% of whom had tumors exceeding UNOS priority criteria, experienced a 2-year survival of 60% with acceptable recurrence rates (26%).
The present study confirms the success of transplantation for HCC in early-stage disease and adds to the growing body of evidence that stage III disease also may be successfullymanagedwithtransplantation.Thisstudyisunique, however, in comparing the results of transplanation in HCC patients with those of patients without cancer. Our matching strategy, which specifically includes year of transplantation, decreases the possibility of confounding based on era of transplantation. Most patients with stage IV disease underwent transplantation early in our series (12 of 17 patients before 1996). As with early experience, the results were uniformly poor when considered alone and when compared with those of contemporary controls without HCC. Patients with stages I through III HCC were more evenly distributed throughout the period of study. Although the improved outcomes in these patients could, in part, be attributed to the overall increase in survival seen in the past 2decadesforlivertransplantation,comparisonwithmatched controls confirms that HCC patients undergoing transplantation enjoy survival comparable to that of non-HCC patients undergoing transplantation. Overall and disease-free survival must be considered when evaluating the results of transplantation for HCC. Specifically with regard to patients with stage III disease, we believe that the case-matched data in this report support the call to expand liver transplantation as a treatment option to those with more advanced HCC. We found an overall 5-year survival rate of 65% in patients with stage III HCC, with only 1 recurrence in 9 cases. This Abbreviation: HCC, hepatocellular carcinoma. *One-, 3-, and 5-year survival rates did not differ significantly between groups (P = .44). compared favorably with lower-stage disease, and survival after transplantation was comparable to that of the non-HCC matched cohort. Indeed, survival after liver transplantation for HCC is more likely a function of intrinsic biological characteristicsofthetumor,suchasmicrovascularinvasion,rather than simply of tumor size. 33, 34 While the data reported herein are compelling, our study has several limitations. Although our liver transplant database is maintained prospectively, this report represents a retrospective review over 17 years. Inherent in a casecontrol study design is the possibility that patients are not equivalent matches. In addition, although pretransplant adjuvant therapy has been evaluated favorably in a prospective study, 11 we did not assess its impact in our population of patients who variously received such therapy. Several authors have addressed the issue of possible disease progression while awaiting a suitable donor liver. 29, 35 Because the intent of this study was to examine outcome after transplantation for HCC, the impact of a potential delay in treatment was not included in our evaluation. Since the UNOS criteria went into effect, we have stopped performing transplantation in patients with advanced disease on a routine basis, and thus it will be difficult to accumulate additional experience with transplantation for stage III disease outside the confines of a clinical trial. However, as many as 30% of HCC patients with stage I or II disease as determined by preoperative imaging are found to have more advanced disease on the basis of explant pathological findings, and this may introduce additional bias in this report. 36, 37 Improvements in diagnostic imaging may reduce the impact of this problem in the future.
CONCLUSIONS
This retrospective review of our experience with liver transplantation for HCC supports the use of this treatment modality for patients with early-stage disease. Furthermore, patients with stage III disease had outcomes similar to those with less advanced malignancy as well as to non-HCC matched controls. On the basis of these findings, we support the expansion of special priority for liver transplantation to those with stage III HCC. 
